Skip to main content
    Z

    Zevra Therapeutics Inc. (ZVRA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.25
    +0.17 (+1.87%)

    Market Cap: $540.30M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Zevra Therapeutics Inc. (ZVRA) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Zevra Therapeutics (ZVRA) trades at 11.6x trailing earnings and 3.7x sales. Its P/S of 3.7x is below its 5-year median of 9.2x. Its forward P/E is 9.8x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 18.4% higher over the next year. PEG is left out because the growth rate behind it, P/E divided by PEG, is under 2% a year.

    MultipleValue
    P/E (trailing)11.6x
    Forward P/E9.8x
    Price to sales3.7x
    Price to book2.3x
    EV/EBITDA5.0x
    Price to FCF14.4x
    EV/FCF11.2x
    PEGN/A
    FCF yield7.0%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S3.7x9.2xN/A
    P/B2.3x3.0xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 7 of the 10 year ends shown that have a P/S, its P/S ranged from 0.9x in 2019 to 17.0x in 2024.

    Year endPriceP/EP/SP/B
    2025$8.96149.3x4.7x3.3x
    2024$8.34N/A17.0x11.3x
    2023$6.55N/A8.9x4.4x
    2022$4.59N/A15.6x2.1x
    2021$8.71N/A7.4x2.4x
    2020$11.20N/A3.3xN/A
    2019$6.06N/A0.9xN/A
    2018$28.48N/AN/AN/A
    2017$64.80N/AN/AN/A
    2016$47.20N/AN/AN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ZVRA

    What is ZVRA's forward P/E ratio?

    Zevra Therapeutics has a forward P/E ratio of 9.8x.

    Is ZVRA stock overvalued?

    GNG's valuation label for ZVRA is Undervalued.

    What is ZVRA's price to sales ratio?

    Zevra Therapeutics has a price to sales ratio of 3.7x.